BURLINGAME, Calif., April 4, 2008 (PRIME NEWSWIRE) -- Urigen Pharmaceuticals, Inc. (OTCBB:URGP) (http://www.urigen.com), announced the termination of the Development and License Agreement for intranasal testosterone with M et P Patent AG, effective April 2, 2008 and will focus its development efforts and resources on URG101 and accelerate its development of URG301.
URG101 targets Painful Bladder Syndrome and has recently reported a positive phase II clinical trial interim analysis. URG301 is a female urethral suppository targeting urethritis and acute urgency and nocturia secondary to overactive bladder.
About Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's product development programs target significant unmet medical needs and major market opportunities in urology. URG101 targets painful bladder syndrome/interstitial cystitis, which affects approximately 10.5 million men and women in North America. Urigen's URG301 project targets urethritis and acute urgency in patients diagnosed with an overactive bladder. For further information, please visit Urigen's website at http://www.urigen.com.
About M et P Patent AG
M et P (www.mattern-pharmaceuticals.com) owns a proprietary nasal drug delivery technology. Apart from the product Nasobol(r) and based on that technology, the Company develops drugs especially to improve Central Nervous System disorders.
Forward-Looking Statement
This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors associated with our Company, please review our SEC filings.